Neuren Pharmaceuticals Limited

Company Profile

Neuren Pharmaceuticals Limited had its IPO on under the ticker symbol NURPF.

The company operates in the Healthcare sector and Biotechnology industry. Neuren Pharmaceuticals Limited has a staff strength of 0 employees.

Stock update

Shares of Neuren Pharmaceuticals Limited opened at $7.49 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.49 - $7.49, and closed at $7.49.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Neuren Pharmaceuticals Limited have slipped by -10.19%.

Neuren Pharmaceuticals Limited's Key Ratios

Neuren Pharmaceuticals Limited has a market cap of $965.96 million, indicating a price to book ratio of 27.9567 and a price to sales ratio of 203.9471.

In the last 12-months Neuren Pharmaceuticals Limited’s revenue was $78.34 million with a gross profit of $2.71 million and an EBITDA of $54.76 million. The EBITDA ratio measures Neuren Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Neuren Pharmaceuticals Limited’s operating margin was 69.88% while its return on assets stood at 51.8% with a return of equity of 88.06%.

In Q2, Neuren Pharmaceuticals Limited’s quarterly earnings growth was a positive 4628.8% while revenue growth was a positive 382.2%.

Neuren Pharmaceuticals Limited’s PE and PEG Ratio

Forward PE

22.2222

Trailing PE

26.75

PEG

Its diluted EPS in the last 12-months stands at $0.28 per share while it has a forward price to earnings multiple of 22.2222 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neuren Pharmaceuticals Limited’s profitability.

Neuren Pharmaceuticals Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -56.9612. Its price to sales ratio in the trailing 12-months stood at 203.9471.

Neuren Pharmaceuticals Limited stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$43.27 million

Total Liabilities

$1.68 million

Operating Cash Flow

$-5000.00

Capital Expenditure

$5000

Dividend Payout Ratio

0%

Neuren Pharmaceuticals Limited ended 2024 with $43.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $43.27 million while shareholder equity stood at $41.59 million.

Neuren Pharmaceuticals Limited ended 2024 with $0 in deferred long-term liabilities, $1.68 million in other current liabilities, 167740000.00 in common stock, $-118693000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $40.18 million and cash and short-term investments were $40.18 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Neuren Pharmaceuticals Limited’s total current assets stands at $43.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.09 million compared to accounts payable of $258000.00 and inventory worth $0.

In 2024, Neuren Pharmaceuticals Limited's operating cash flow was $-5000.00 while its capital expenditure stood at $5000.

Comparatively, Neuren Pharmaceuticals Limited paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$7.49

52-Week High

$9.888

52-Week Low

$4.15

Analyst Target Price

$

Neuren Pharmaceuticals Limited stock is currently trading at $7.49 per share. It touched a 52-week high of $9.888 and a 52-week low of $9.888. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $8.38 and 200-day moving average was $7.43 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1400.2% of the company’s stock are held by insiders while 1294.8% are held by institutions.